CytomX Therapeutics, Inc. Liabilities Assumed
CytomX Therapeutics, Inc. (CTMX) reported Liabilities Assumed of $1.86 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2016-11-03.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2016-11-03
- CytomX Therapeutics, Inc. liabilities assumed for the quarter ending 2015-09-30 was $1.71M.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month |
|---|---|---|---|
| 2015-09-30 | $1.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.86M 10-Q · filed 2016-11-03 | |
| 2015-06-30 | $157.00K 10-Q · filed 2016-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |